34086 Rapid response of truncal acne with oral sarecycline

Abstract

Truncal acne affects 60-70% of acne patients and larger surface areas than facial acne. Topical treatment application becomes more difficult. Oral sarecycline, a narrow-spectrum, third-generation tetracycline-class antibiotic, is FDA-approved for moderate-to-severe acne vulgaris in patients aged 9 and older. Sarecycline’s potent anti-inflammatory activity, activity against Cutibacterium acnes and clinically relevant Gram-positive bacteria, but reduced activity against enteric Gram-negative bacteria, may contribute to its favorable safety and tolerability profile.